Table 4 Multivariate analysis of factors associated with good clinical outcomes among patients treated for MDR-TB
| Â | Good treatment outcomes among all MDR TB patients aOR (95% CI) | Good treatment outcomes (excluding patients with hearing loss diagnosed clinically) aOR (95% CI) | Good treatment outcomes (excluding patients with hearing loss diagnosed by audiometry) aOR (95% CI) | |
|---|---|---|---|---|
Sex | Female | 1.00 | 1.00 | 1.00 |
|  | Male | 0.72 (0.4 –1.21) | 0.71 (0.42 – 1.19) | 0.72 (0.44 – 1.21) |
HIV status | HIV infection | 0.64 (0.37 –1.12) | 0.70 (0.39 – 1.20) | 0.66 (0.38 – 1.15) |
TB treatment history | Never treated for TB before | 1.00 | 1.00 | 1.00 |
New TB regimen | 0.93 (0.27 – 3.23) | 0.71 (0.19 – 2.64) | 0.75 (0.20 – 2.77) | |
Retreatment regimen | 0.60 (0.18 – 1.98) | 0.48 (0.13 – 1.69) | 0.48 (0.14 – 1.70) | |
*Treated for MDR TB | 0.16(0.09 – 0.67) | 0.12 (0.02 – 0.70) | 0.11 (0.02 – 0.57) | |
Renal failure at any point | 0.61 (0.36 – 0.98) | 0.46 (0.22 – 0.94) | 0.52 (0.12 – 1.01) | |
Duration of amikacin treatment (in months) | 1.13(1.06 – 1.21) | 1.14 (1.06 – 1.21) | 1.14 (1.05 – 1.22) | |
¶Mean dose of amikacin per kilogram per month | 1.90 (1.12 – 2.99) | 1.90 (1.79 – 3.00) | 1.88 (1.18 – 3.99) | |